Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567137 | 1.00 | EPHX1 (0.51) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL14497217 | 0.90 | EPHX1 (0.58) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL1514783 | 0.84 | EPHX1 (0.64) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL1437840 | 0.82 | EPHX1 (0.74) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL15225875 | 0.81 | EPHX1 (0.76) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL1155492 | 0.79 | EPHX1 (0.57) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL26131308 | 0.79 | EPHX1 (0.74) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL24423875 | 0.79 | POLB (0.56) | EPHX1EPHX2POLBNPC1RAB9A | |
| Bicarbonate SCHEMBL9234681 | 0.78 | EPHX1 (0.72) | EPHX1EPHX2HPGDPTPN2PTPN1 | |
| SCHEMBL2134650 | 0.78 | EPHX1 (0.43) | EPHX1HPGDPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | EPHX1 3042/4885EPHX2 3623/4885HPGD 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.